Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -114.71% is 77% above its 5-year average of -508.87%, near the high end of its 5-year range (-15137.23%–729.25%).
97.64% above its 12-month average of -4861.68%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 76.92%.
EBITDA MARGIN
-114.71%
EBITDA MARGIN AVG TTM
-4861.68%
EBITDA MARGIN AVG 3Y
-3022.31%
EBITDA MARGIN AVG 5Y
-508.87%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+97.64%
CURRENT VS 3Y AVG
+96.20%
CURRENT VS 5Y AVG
+77.46%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MeiraGTx Holdings plc
Market Cap
$981.66M
EBITDA Margin
-114.71%
TTM Avg
-4861.68%
3Y Avg
-3022.31%
5Y Avg
-508.87%
Market Cap
$982.46M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$978.09M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$973.93M
EBITDA Margin
17.12%
TTM Avg
8.95%
3Y Avg
16.20%
5Y Avg
17.02%
Market Cap
$996.65M
EBITDA Margin
-31.64%
TTM Avg
-36.17%
3Y Avg
-63.38%
5Y Avg
-163.90%
Market Cap
$998.69M
EBITDA Margin
-358.45%
TTM Avg
-358.45%
3Y Avg
-358.45%
5Y Avg
-358.45%
Market Cap
$1.01B
EBITDA Margin
-351.42%
TTM Avg
-184.18%
3Y Avg
-130.50%
5Y Avg
-161.84%
Market Cap
$953.81M
EBITDA Margin
-1113.67%
TTM Avg
-2254.05%
3Y Avg
-2254.05%
5Y Avg
-2254.05%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | $981.66M | -114.71% | -4861.68% | -3022.31% | -508.87% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | N/A | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 17.12% | 8.95% | 16.20% | 17.02% |
| Vor Biopharma Inc. (VOR)vs › | $992.14M | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | -31.64% | -36.17% | -63.38% | -163.90% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | -358.45% | -358.45% | -358.45% | -358.45% |
| Immatics N.V. (IMTX)vs › | $1.01B | -351.42% | -184.18% | -130.50% | -161.84% |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | -1113.67% | -2254.05% | -2254.05% | -2254.05% |
| Savara Inc. (SVRA)vs › | $952.91M | -19083.66% | -19083.66% | -19083.66% | -24221442.25% |
Gross Margin
97.2%
EBITDA Margin
-114.7%
Operating Margin
-130.2%
Net Margin
19.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 76.92% |
| 2026-03-31 | -12904.10% |
| 2025-12-31 | 39.34% |
| 2025-09-30 | -10393.41% |
| 2025-06-30 | -1127.15% |
| 2025-03-31 | -1999.74% |
| 2024-12-31 | -133.55% |
| 2024-09-30 | -337.13% |
| 2024-06-30 | -15137.23% |
| 2024-03-31 | -6240.60% |
| 2023-12-31 | -1953.04% |
| 2023-09-30 | -573.84% |
| 2023-06-30 | -721.41% |
| 2023-03-31 | -859.87% |
| 2022-12-31 | 729.25% |
| 2022-09-30 | -431.48% |
| 2022-06-30 | -201.44% |
| 2022-03-31 | -472.50% |
| 2021-12-31 | -28.81% |
| 2021-09-30 | -295.31% |
| 2021-06-30 | -360.97% |
| 2021-03-31 | -441.22% |
| 2020-12-31 | -313.31% |
| 2020-09-30 | -144.64% |
| 2020-06-30 | -981.57% |
| 2020-03-31 | -353.12% |
| 2019-12-31 | -68.76% |
| 2019-09-30 | -289.56% |
| 2019-06-30 | -1044.10% |
| 2019-03-31 | -2572.25% |
